Loading…
Loading…
The iShares Genomics Immunology and Healthcare ETF (IDNA) is designed to mirror the investment performance of a specific index. This index comprises companies operating in both mature and emerging global markets. These businesses are strategically chosen for their potential to capitalize on sustained innovation and expansion within the crucial fields of genomics, immunology, and bioengineering.
Is IDNA's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
IDNA jumped 13.53% in one day on 2.8x average volume after three catalysts, including Moderna's and Merck's positive Phase 3 INTerpath-001 data. IDNA trades at a 14.90x forward P/E, implying a 6.7% theoretical earnings yield. Closing the valuation gap with XBI's forward multiple would mechanically add about 29.5% to IDNA's price as a one-time re-rating.
iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 6,747 shares, a growth of 428.3% from the December 31st total of 1,277 shares. Approximately 0.1% of the shares of
The iShares Genomics Immunology and Healthcare ETF is invested in 49 companies involved in genomics, immunology and bioengineering. Compared with the biotechnology benchmark IBB, IDNA has value characteristics, but has greatly underperformed, losing over 20% since its inception. Among genomics-focused ETFs, PBE offers a relatively safer choice with better performance and lower volatility.